Glycobiology Advance Access originally published online on April 28, 2004
Glycobiology 2004 14(8):681-692; doi:10.1093/glycob/cwh090
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Glycobiology vol. 14 no. 8 © Oxford University Press 2004; all rights reserved.
Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1)
2 NEMOD GmbH & Co. KG, Robert-Rössle-Str. 10, D-13125 Berlin, Germany; 3 Max Delbrück Centre for Molecular Medicine, D-13125 Berlin-Buch, Germany; 4 Institute of Organic Chemistry, University of Hamburg, D-20146 Hamburg, Germany; and 5 Glycotope GmbH, D-13125 Berlin-Buch, Germany
Received on February 6, 2004; revised on April 20, 2004; accepted on April 20, 2004
Glycosylation determines essential biological functions of epithelial mucins in health and disease. We report on the influence of glycosylation of the immunodominant DTR motif of MUC1 on its antigenicity. Sets of novel glycopeptides were synthesized that enabled us to examine sole and combined effects of peptide length (number of repeats) and O-glycosylation with GalNAc at the DTR motif on the binding patterns of 22 monoclonal antibodies recognizing this motif. In case of unglycosylated peptides almost all antibodies bound better to multiple MUC1 tandem repeats. Glycosylation at the DTR led to enhanced binding in 11 cases, whereas 10 antibodies were not influenced in binding, and one was inhibited. In nine of the former cases both length and DTR glycosylation were additive in their influence on antibody binding, suggesting that both effects are different. Improved binding to the glycosylated DTR motif was exclusively found with antibodies generated against tumor-derived MUC1. Based on these data a tumor-specific MUC1 epitope is defined comprising the ...PDTRP... sequence in a particular conformation essentially determined by O-glycosylation at its threonine with either GalNAc
1 or a related short glycan. The results can find application in the field of MUC1-based immunotherapy.
1 To whom correspondence should be addressed; e-mail: uwe.karsten{at}nemod.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. J Storr, L. Royle, C. J Chapman, U. M A. Hamid, J. F Robertson, A. Murray, R. A Dwek, and P. M Rudd The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum Glycobiology, June 1, 2008; 18(6): 456 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Santos-Silva, A. Fonseca, T. Caffrey, F. Carvalho, P. Mesquita, C. Reis, R. Almeida, L. David, and M. A. Hollingsworth Thomsen-Friedenreich antigen expression in gastric carcinomas is associated with MUC1 mucin VNTR polymorphism Glycobiology, May 1, 2005; 15(5): 511 - 517. [Abstract] [Full Text] [PDF]
|
|